Latest Articles

Publication Date
Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care - CancerNetwork

Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care CancerNetwork

Published: May 15, 2026, 2:05 p.m.
Bidirectional Mendelian Randomization and Single‑Cell RNA Sequencing Reveal an NK Cell-Mediated Causal Link Between Endometriosis and Endometrial Cancer.

Endometriosis is a chronic estrogen-dependent inflammatory disease that shares epidemiological and pathological features with endometrial cancer. However, the cellular and genetic mechanisms underlying this association remain unclear.

Published: May 15, 2026, midnight
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart

Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart

Published: May 14, 2026, 4:30 p.m.
Karyopharm completes endometrial cancer trial enrollment - Investing.com

Karyopharm completes endometrial cancer trial enrollment Investing.com

Published: May 14, 2026, 11:52 a.m.
Karyopharm completes endometrial cancer trial enrollment By Investing.com - Investing.com Canada

Karyopharm completes endometrial cancer trial enrollment By Investing.com Investing.com Canada

Published: May 14, 2026, 11:45 a.m.
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M - Stock Titan

Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M Stock Titan

Published: May 14, 2026, 11:30 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire

Published: May 14, 2026, 11:30 a.m.
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - Moomoo

Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Moomoo

Published: May 14, 2026, 11:30 a.m.
Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer - OncLive

Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer OncLive

Published: May 14, 2026, 12:06 a.m.
Risks of gynecological and breast cancers in women with endometriosis or adenomyosis: A nationwide cohort study.

Endometriosis has been associated with several risk factors for cancer, and population-based research has shown that women with endometriosis have a higher risk of several types of cancer. The aim …

Published: May 14, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!